Recent developments in the pathology of Parkinson’s disease
1
Institute of Clinical Neurobiology, Vienna, Austria
|
Publication type: Book Chapter
Publication date: 2002-01-01
SJR: —
CiteScore: —
Impact factor: —
ISSN: 03036995
PubMed ID:
12456078
Abstract
Parkinson’s disease (PD) is morphologically characterized by progressive loss of neurons in the substantia nigra pars compacta (SNpc) and other subcortical nuclei associated with intracytoplasmic Lewy bodies and dystrophic (Lewy) neurites mainly in subcortical nuclei and hippocampus und, less frequently in cerebral cortex. SN cell loss is significantly related to striatal dopamine (DA) deficiency as well as to both the duration and clinical severity of disease, The two major clinical subtypes of PD show different morphologic lesion patterns: the akinetic-rigid form has more severe cell loss in the ventrolateral part of SN with negative correlation to DA loss in the posterior putamen, and motor symptoms related to overacitivty of the GABAergic “indirect” motor loop, which causes inhibition of the glutamatergic thalamocortical pathway and reduced cortical activation. The tremor-dominant type shows more severe cell loss in the medial SNpc and retrorubal field A 8, which project to the matrix of the dorsolateral striatum and ventromedial thalamus, thus causing hyperactivity of thalamomotor and cerebellar projections. These and experimental data suggesting different pathophysiological mechanisms for the major clinical subtypes of PD may have important therapeutic implications. Lewy bodies, the morphologic markers of PD, are composed of hyperphosphorylated neurofilament proteins, lipids, redox-active iron, ubiquitin,
and α-synuclein, showing a continuous accumulation in the periphery and of
ubiquitin in the central core. α-synuclein, is usually unfolded in α-helical form.
By gene mutation, environmental stress or other factors it can be transformed
to β-folding which is sensible to self-aggregation in filamentous fibrils and
formation of insoluble intracellular inclusions that may lead to functional
disturbances and, finally , to death of involved neurons. While experimental
and tissue culture studies suggest that apoptosis, a genetically determined
form of programmed cell death, represents the most common pathway in
neurodegeneration, DNA fragmentation, overexpression of proapoptotic
proteins and activated caspase-3, the effector enzyme of the terminal
apopoptic cascade, have only extremely rarely been detected in SN of PD
brains. This is in accordance with the rapid course of apoptotis and the extremely slow progression of the neurodegenerative process in PD. The
biological role of Lewy bodies and other intracellular inclusions, the mechanisms
of the intracellular aggregation of insoluble protein deposits, and their
implication for cellular dysfunction resulting in neurodegeneration and cell
demise are still unresolved. Further elucidation of the basic molecular mechanisms
of cytoskeletallesions will provide better insight into the pathogenesis
of neurodegeneration in PD and related disorders.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
5
|
|
|
Movement Disorders
5 publications, 4.95%
|
|
|
Parkinsonism and Related Disorders
4 publications, 3.96%
|
|
|
PLoS ONE
3 publications, 2.97%
|
|
|
CNS Neuroscience and Therapeutics
3 publications, 2.97%
|
|
|
Brain Research
2 publications, 1.98%
|
|
|
Neuroscience
2 publications, 1.98%
|
|
|
Frontiers in Aging Neuroscience
2 publications, 1.98%
|
|
|
Journal of Neurology
2 publications, 1.98%
|
|
|
Neurobiology of Aging
2 publications, 1.98%
|
|
|
Neuroscience Letters
2 publications, 1.98%
|
|
|
Biochemical and Biophysical Research Communications
2 publications, 1.98%
|
|
|
Journal of Neurochemistry
2 publications, 1.98%
|
|
|
Human Brain Mapping
2 publications, 1.98%
|
|
|
Journal of Neuropathology and Experimental Neurology
2 publications, 1.98%
|
|
|
Current Medicinal Chemistry
1 publication, 0.99%
|
|
|
Molecular Brain Research
1 publication, 0.99%
|
|
|
Journal of Cognitive Neuroscience
1 publication, 0.99%
|
|
|
Behavioural Pharmacology
1 publication, 0.99%
|
|
|
Future Medicinal Chemistry
1 publication, 0.99%
|
|
|
Collection of Czechoslovak Chemical Communications
1 publication, 0.99%
|
|
|
Substance Abuse: Research and Treatment
1 publication, 0.99%
|
|
|
International Journal of Molecular Sciences
1 publication, 0.99%
|
|
|
Scientific Reports
1 publication, 0.99%
|
|
|
Experimental Brain Research
1 publication, 0.99%
|
|
|
Journal of NeuroImmune Pharmacology
1 publication, 0.99%
|
|
|
Comparative Clinical Pathology
1 publication, 0.99%
|
|
|
Archives of Toxicology
1 publication, 0.99%
|
|
|
CNS Drugs
1 publication, 0.99%
|
|
|
Journal of Molecular Neuroscience
1 publication, 0.99%
|
|
|
1
2
3
4
5
|
Publishers
|
5
10
15
20
25
30
|
|
|
Elsevier
30 publications, 29.7%
|
|
|
Wiley
16 publications, 15.84%
|
|
|
Springer Nature
12 publications, 11.88%
|
|
|
Taylor & Francis
5 publications, 4.95%
|
|
|
Public Library of Science (PLoS)
3 publications, 2.97%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
2 publications, 1.98%
|
|
|
Frontiers Media S.A.
2 publications, 1.98%
|
|
|
Oxford University Press
2 publications, 1.98%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 0.99%
|
|
|
MIT Press
1 publication, 0.99%
|
|
|
Institute of Organic Chemistry & Biochemistry
1 publication, 0.99%
|
|
|
SAGE
1 publication, 0.99%
|
|
|
MDPI
1 publication, 0.99%
|
|
|
Georg Thieme Verlag KG
1 publication, 0.99%
|
|
|
Pleiades Publishing
1 publication, 0.99%
|
|
|
The Society for Free Radical Research Japan
1 publication, 0.99%
|
|
|
Zhejiang University Press
1 publication, 0.99%
|
|
|
American Society of Neuoradiology
1 publication, 0.99%
|
|
|
Hindawi Limited
1 publication, 0.99%
|
|
|
Society for Neuroscience
1 publication, 0.99%
|
|
|
Walter de Gruyter
1 publication, 0.99%
|
|
|
American Psychological Association (APA)
1 publication, 0.99%
|
|
|
IMR Press
1 publication, 0.99%
|
|
|
5
10
15
20
25
30
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
101
Total citations:
101
Citations from 2024:
2
(1.98%)
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Jellinger K. A. Recent developments in the pathology of Parkinson’s disease // Advances in Down Syndrome Research. 2002. Vol. 62. pp. 347-384.
GOST all authors (up to 50)
Copy
Jellinger K. A. Recent developments in the pathology of Parkinson’s disease // Advances in Down Syndrome Research. 2002. Vol. 62. pp. 347-384.
Cite this
RIS
Copy
TY - GENERIC
DO - 10.1007/978-3-7091-6139-5_33
UR - https://doi.org/10.1007/978-3-7091-6139-5_33
TI - Recent developments in the pathology of Parkinson’s disease
T2 - Advances in Down Syndrome Research
AU - Jellinger, K. A.
PY - 2002
DA - 2002/01/01
PB - Springer Nature
SP - 347-384
IS - 62
PMID - 12456078
SN - 0303-6995
ER -
Cite this
BibTex (up to 50 authors)
Copy
@incollection{2002_Jellinger,
author = {K. A. Jellinger},
title = {Recent developments in the pathology of Parkinson’s disease},
publisher = {Springer Nature},
year = {2002},
number = {62},
pages = {347--384},
month = {jan}
}